All Voices
Researcher· Evidence Review

Loren Pickart

The biochemist who discovered GHK-Cu in 1973

Last reviewed: April 8, 2026Topics: Copper Peptides, GHK-Cu, Skin Biology, Gene Expression
No authentic CC-licensed photo located as of this review. Placeholder shown.

Bio

Loren Pickart is the biochemist who, in 1973, first reported the biological activity of the small tripeptide glycyl-L-histidyl-L-lysine (GHK) — the compound now widely known in its copper-bound form, GHK-Cu. Over the subsequent five decades he has published consistently on copper peptides, particularly their roles in wound healing, skin regeneration, and, more recently, broad gene expression modulation.

Background

Pickart completed his PhD in biochemistry at UCSF and identified GHK while studying a factor in human albumin that affected hepatocyte behavior. He spent his early career in academic and industry research labs before founding Skin Biology in 1994, a company that sells topical copper peptide skincare products. Unlike many peptide-adjacent figures, his peer-reviewed output predates and underpins the commercial field that now exists around copper peptides.

What They Do

Pickart's scientific work characterizes GHK-Cu's effects on fibroblasts, collagen synthesis, wound healing, and — in more recent papers — its ability to modulate gene expression across thousands of genes toward patterns associated with younger tissue. His commercial work through Skin Biology focuses on topical formulations. He does not sell injectable GHK-Cu, but his writing has discussed the possibility that injectable or systemic copper peptides could have broader anti-aging applications.

Research Record

Pickart has an unusually long and consistent publication record on a single compound. Key contributions include the original 1973 identification of GHK, the 1988 Maquart paper (co-authored with collaborators) on GHK-Cu in wound healing, and later gene expression analyses reporting modulation of thousands of genes in response to GHK-Cu in cultured cells. His peer-reviewed record is legitimate; the interpretation of the gene expression data is where caveats are warranted.

Our Evidence Summary

Pickart is one of the rare peptide figures where the science genuinely came first and the commercial interest came later. Topical GHK-Cu has meaningful wound healing and skin evidence; his gene expression work has been replicated in cultured cells. The weak link is the jump from in vitro gene expression effects to claims about whole-body anti-aging in humans. His commercial role in Skin Biology should be disclosed to readers but should not lead them to dismiss his peer-reviewed record, which is substantial.

Claim-by-Claim Evidence Review

Strong Evidence

Topical GHK-Cu accelerates wound healing and stimulates collagen

Multiple in vivo and clinical studies dating back decades show GHK-Cu benefits in wound healing and dermal remodeling. This is well-established dermatologic biology.

Moderate Evidence

Topical GHK-Cu in skincare produces measurable improvements in skin appearance

Clinical studies of GHK-Cu creams report reductions in wrinkles and improved firmness, though many were small and some were industry-funded. Overall the topical cosmetic evidence is reasonable.

Moderate Evidence

GHK-Cu modulates the expression of thousands of genes toward a younger profile

In vitro gene expression analyses do show broad transcriptional effects. Whether those changes correspond to meaningful tissue-level rejuvenation in humans is a separate, much weaker question.

Speculative

Injectable or systemic GHK-Cu extends human lifespan or healthspan

There are no human clinical trials of injected GHK-Cu with longevity endpoints. This claim is extrapolation from in vitro and rodent work, not clinical data.

Limited Evidence

GHK-Cu has anti-cancer activity

Some in vitro and early in vivo studies are suggestive, but the clinical evidence is nowhere near sufficient to support clinical anti-cancer claims.

Moderate Evidence

Copper peptides help reverse sun damage and photoaging

Reasonable evidence from topical studies supports benefits in photoaged skin, though effect sizes are modest and comparable to or incremental over established retinoid therapy.

Moderate Evidence

Endogenous GHK levels decline with age

Pickart has reported this in his own work; independent replication is limited. Plausible and consistent with his broader framework but should be taken as tentative.

Related Reading

Editorial note: This page evaluates the public claims and protocols of a third party. We do not receive compensation from any of the people profiled and have no affiliation with them. Evidence levels are assigned by reviewing primary literature and reflect the state of the science as of April 2026. Science evolves — we update these reviews when new evidence emerges. This is not medical advice; consult a qualified physician before changing your health practices.